The Valley Desk

ArticleJCO precision oncologyPublished

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
JCO precision oncology
Published
Subject terms
Humans; Melanoma; Azetidines; Piperidines; Proto-Oncogene Proteins B-raf; Antineoplastic Agents; Mutation; Vemurafenib
PubMed ID
38096472
PubMed Central ID
PMC10735080
Added to directory
Source checked

Report a correction or request removal